Company profile · free preview

Revolution Medicines, Inc.

RVMD · NASDAQ · Healthcare · Updated 10/27/2026

Revenue

Fiscal 2025

Net income

(1.1B)

Fiscal 2025

Free cash flow

(913.7M)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year	2025	2024	2023	2022	2021
Revenue	$0	$0	$11.6M	$35.4M	$29.4M
Net income	(1.1B)	(600.1M)	(436.4M)	(248.7M)	(187.1M)
Diluted EPS	—	—	—	—	—
Operating cash flow	(897.7M)	(557.4M)	(350.6M)	(224.4M)	(147.2M)
Free cash flow	(913.7M)	(567.7M)	(358.3M)	(235.2M)	(153.7M)
Cash	$383.7M	$543.1M	$696.1M	$161.4M	$108.5M
Total debt	—	—	—	—	—

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

—

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $51.4MBar width = share of $51.4M (spending exceeded operating cash flow)

Operating cash flow	($2.2B)
Capital expenditure	($51.4M)
Free cash flow	($2.2B)
Share buybacks	—
Dividends paid	—
Acquisitions (net)	—
Net debt issued / (repaid)	—
Stock-based compensation (non-cash)	—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.